Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191324 | 0.91 | CYP4F2 (0.63) | KMT2AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL19068062 | 0.86 | MAPT (0.58) | KMT2AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL6295262 | 0.85 | NPC1 (0.70) | KMT2AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL12440458 | 0.85 | P2RX3 (0.58) | ALDH1A1LTA4HEPHX2LMNA | |
| SCHEMBL3192546 | 0.84 | SRD5A2 (0.58) | KMT2AALDH1A1NPC1KLK7CYP4F2 | |
| SCHEMBL31324190 | 0.83 | MAPT (0.63) | KMT2AMAPTALDH1A1KLK7POLB | |
| SCHEMBL7558146 | 0.83 | KMT2A (0.56) | KMT2AALDH1A1NPC1RAB9AKLK7 | |
| SCHEMBL5924358 | 0.83 | CYP4F2 (0.54) | KMT2AALDH1A1NPC1RAB9AKLK7 | |
| SCHEMBL2367221 | 0.82 | POLB (0.56) | KMT2AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL16870234 | 0.81 | CYP4F2 (0.53) | ALDH1A1NPC1RAB9ACYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1226128-B1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6716845-B2 | Barbituric acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1383746-A2 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-28 | — | — | EP | disclosed |
| US-6498252-B1 | Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds | HOFFMANN-LA ROCHE INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020187991-A1 | Barbituric acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | US | disclosed |
| WO-2002079170-A2 | PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
| EP-1226128-A1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001025217-A1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-12 | — | — | WO | disclosed |
| US-4168385-A | LOWERING OF STEROL AND TRIGLYCERIDE SERUM LEVELS | AMERICAN CYANAMID COMPANY (US) | 1979-09-18 | — | — | US | disclosed |
| US-4125729-A | Hypolipemic α-aryloxy para substituted phenyl acetic acid compounds | AMERICAN CYANAMID COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187991-A1 | Barbituric acid derivatives | GABBR1, GABBR2, TUBB6 | KMT2A 3474/4885MAPT 2414/4885ALDH1A1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.